Dihydrexidine is a moderately selective full agonist at the dopamine D1 and D5 receptors (1,2). It has been shown to have antiparkinson effects. It also has the ability to improving the cognitive and working memory deficits in schizophrenia and schizotypal disorder.
A potent, full efficacy dopamine D 1 agonist which shows no agonist activity at peripheral D 2 receptors or adrenoceptors at doses which cause maximal stimulation of D 1 sites. The compound appears to be fully bioavailable in brain and exhibits profound antiparkinsonism effects in vivo .
Dihydrexidine has poor oral bioavailability and a relatively short half-life of 1 to 2 h[3].
Dihydrexidine (3 mg/kg; i.p.) produces prominent dopamine D1 receptor agonist effects in vivo[4].
| Animal Model: | Adult male Sprague–Dawley rats (275-300 g)[4] |
| Dosage: | Adult male Sprague–Dawley rats (275-300 g)[4] |
| Administration: | Intraperitoneal injection |
| Result: | Produces prominent dopamine D1 receptor agonist effects in vivo |
D1 Receptor: 10 nM (IC50)
